Propranolol Decreases Fear Expression by Modulating Fear Memory Traces.
Arc
Contextual fear conditioning
Engram
Memory
Propranolol
Trace
c-Fos
Journal
Biological psychiatry
ISSN: 1873-2402
Titre abrégé: Biol Psychiatry
Pays: United States
ID NLM: 0213264
Informations de publication
Date de publication:
15 06 2021
15 06 2021
Historique:
received:
24
06
2020
revised:
11
01
2021
accepted:
12
01
2021
pubmed:
27
3
2021
medline:
29
6
2021
entrez:
26
3
2021
Statut:
ppublish
Résumé
Posttraumatic stress disorder can develop after a traumatic event and results in heightened, inappropriate fear and anxiety. Although approximately 8% of the U.S. population is affected by posttraumatic stress disorder, only two drugs have been approved by the Food and Drug Administration to treat it, both with limited efficacy. Propranolol, a nonselective β-adrenergic antagonist, has shown efficacy in decreasing exaggerated fear, and there has been renewed interest in using it to treat fear disorders. Here, we sought to determine the mechanisms by which propranolol attenuates fear by utilizing an activity-dependent tagging system, ArcCreER Propranolol decreased fear expression only when administered before a delayed context reexposure. Fear memory traces were affected in the dorsal dentate gyrus and basolateral amygdala after propranolol administration in the ArcCreER These data indicate that propranolol may decrease fear expression by altering network-correlated activity and by weakening the reactivation of the initial traumatic memory trace. This work contributes to the understanding of noradrenergic drugs as therapeutic aids for patients with posttraumatic stress disorder.
Sections du résumé
BACKGROUND
Posttraumatic stress disorder can develop after a traumatic event and results in heightened, inappropriate fear and anxiety. Although approximately 8% of the U.S. population is affected by posttraumatic stress disorder, only two drugs have been approved by the Food and Drug Administration to treat it, both with limited efficacy. Propranolol, a nonselective β-adrenergic antagonist, has shown efficacy in decreasing exaggerated fear, and there has been renewed interest in using it to treat fear disorders.
METHODS
Here, we sought to determine the mechanisms by which propranolol attenuates fear by utilizing an activity-dependent tagging system, ArcCreER
RESULTS
Propranolol decreased fear expression only when administered before a delayed context reexposure. Fear memory traces were affected in the dorsal dentate gyrus and basolateral amygdala after propranolol administration in the ArcCreER
CONCLUSIONS
These data indicate that propranolol may decrease fear expression by altering network-correlated activity and by weakening the reactivation of the initial traumatic memory trace. This work contributes to the understanding of noradrenergic drugs as therapeutic aids for patients with posttraumatic stress disorder.
Identifiants
pubmed: 33766406
pii: S0006-3223(21)00047-0
doi: 10.1016/j.biopsych.2021.01.005
pmc: PMC8201901
mid: NIHMS1710152
pii:
doi:
Substances chimiques
Propranolol
9Y8NXQ24VQ
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1150-1161Subventions
Organisme : NIMH NIH HHS
ID : F31 MH125656
Pays : United States
Organisme : NIH HHS
ID : DP5 OD017908
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD101402
Pays : United States
Organisme : NIA NIH HHS
ID : R21 AG064774
Pays : United States
Organisme : NIA NIH HHS
ID : R56 AG058661
Pays : United States
Organisme : NINDS NIH HHS
ID : R21 NS114870
Pays : United States
Organisme : NICHD NIH HHS
ID : T32 HD007430
Pays : United States
Organisme : NIMH NIH HHS
ID : F31 MH121023
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
Références
Arch Gen Psychiatry. 1995 Dec;52(12):1048-60
pubmed: 7492257
Neuroscience. 2007 Apr 25;146(1):298-305
pubmed: 17337326
Nature. 2012 Mar 22;484(7394):381-5
pubmed: 22441246
Drugs. 1988 Dec;36(6):773-83
pubmed: 2905981
Neuropsychopharmacology. 2017 Dec;42(13):2537-2544
pubmed: 28462941
Biol Psychiatry. 2009 May 15;65(10):887-92
pubmed: 19246030
Hippocampus. 2017 Oct;27(10):1110-1122
pubmed: 28667669
Nature. 2014 Nov 13;515(7526):269-73
pubmed: 25383519
Synapse. 2000 Jun 1;36(3):178-93
pubmed: 10819898
Neurobiol Learn Mem. 2010 Oct;94(3):318-28
pubmed: 20667477
Synapse. 1993 Mar;13(3):206-14
pubmed: 8098879
Front Neural Circuits. 2017 Apr 07;11:23
pubmed: 28439228
Bioinformatics. 2013 Jul 15;29(14):1840-1
pubmed: 23681123
Neuron. 2013 Mar 6;77(5):955-68
pubmed: 23473324
Neuron. 2015 Sep 2;87(5):918-31
pubmed: 26335640
Neuron. 2010 Jan 14;65(1):7-19
pubmed: 20152109
Neuron. 1995 Feb;14(2):433-45
pubmed: 7857651
Acta Physiol Scand Suppl. 1981;500:1-147
pubmed: 6123220
Drugs Context. 2015 Aug 14;4:212286
pubmed: 26322115
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10825-30
pubmed: 12149439
Neuron. 2017 Aug 2;95(3):656-672.e3
pubmed: 28772124
Front Behav Neurosci. 2018 Mar 13;12:43
pubmed: 29593511
Biol Psychiatry. 2015 Dec 15;78(12):880-6
pubmed: 25980916
Front Behav Neurosci. 2013 Dec 23;7:211
pubmed: 24391566
Am J Psychiatry. 2018 May 1;175(5):427-433
pubmed: 29325446
Am J Psychiatry. 2001 Dec;158(12):1982-8
pubmed: 11729013
Nat Neurosci. 2019 May;22(5):753-761
pubmed: 30936555
Am J Health Syst Pharm. 2008 Apr 15;65(8):716-22
pubmed: 18387899
J Psychiatry Neurosci. 2013 Jul;38(4):222-31
pubmed: 23182304
Learn Mem. 2010 Jun 01;17(6):306-13
pubmed: 20516209
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
JAMA. 2000 Apr 12;283(14):1837-44
pubmed: 10770145
PLoS Comput Biol. 2013;9(1):e1002853
pubmed: 23300432
Biochem Biophys Res Commun. 2008 Apr 4;368(2):186-91
pubmed: 18190786
Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5734-8
pubmed: 7777577
Bioinformatics. 2016 Nov 15;32(22):3532-3534
pubmed: 27412086
J Dent Res. 1991 Sep;70(9):1306-8
pubmed: 1918581
Brain Res Bull. 2014 Jun;105:46-60
pubmed: 24374101
Cereb Cortex. 2016 Apr;26(4):1349-64
pubmed: 26804338
Hippocampus. 2016 Jun;26(6):752-62
pubmed: 26662713
Nat Neurosci. 2018 Jan;21(1):139-149
pubmed: 29203898
Science. 2007 Aug 31;317(5842):1230-3
pubmed: 17761885
J Psychopharmacol. 2016 Feb;30(2):128-39
pubmed: 26487439
Behav Neurosci. 2003 Dec;117(6):1378-84
pubmed: 14674855
Behav Neurosci. 1999 Dec;113(6):1189-203
pubmed: 10636298
Science. 2018 Jun 15;360(6394):1239-1242
pubmed: 29903974
Neurobiol Learn Mem. 2016 Apr;130:26-33
pubmed: 26808441
Neuroscience. 2007 Jan 19;144(2):472-81
pubmed: 17097235
Neuropsychopharmacology. 2016 May;41(6):1569-78
pubmed: 26462618
Br J Clin Pharmacol. 1985 Jun;19(6):783-6
pubmed: 2862892
BMC Dev Biol. 2001;1:4
pubmed: 11299042
Nature. 2014 Sep 18;513(7518):426-30
pubmed: 25162525
Learn Mem. 2004 Mar-Apr;11(2):179-87
pubmed: 15054133
Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):E3729-37
pubmed: 26124100
Psychopharmacology (Berl). 2019 Jan;236(1):369-381
pubmed: 30116860
Neuron. 2014 Jul 2;83(1):189-201
pubmed: 24991962
Psychol Med. 2010 Nov;40(11):1839-48
pubmed: 20102667
Neuron. 2009 Jun 25;62(6):757-71
pubmed: 19555645
Cell. 2018 Jan 11;172(1-2):275-288.e18
pubmed: 29328916
Nature. 2015 Jun 18;522(7556):335-9
pubmed: 26085274
Biol Psychiatry. 2012 Feb 15;71(4):380-6
pubmed: 22129757
Psychopharmacology (Berl). 2004 Sep;175(3):342-52
pubmed: 15007536
Nature. 2016 Mar 24;531(7595):508-12
pubmed: 26982728
Neuropsychobiology. 1985;13(4):187-93
pubmed: 4047384
Am J Med. 1982 Jan;72(1):88-94
pubmed: 6120650
J Comp Neurol. 2008 Aug 20;509(6):551-65
pubmed: 18546278
Biol Psychiatry. 2018 Dec 1;84(11):846-856
pubmed: 29615190
Front Behav Neurosci. 2017 Apr 19;11:65
pubmed: 28469565
Hippocampus. 1998;8(6):608-19
pubmed: 9882018
Behav Neurosci. 1999 Dec;113(6):1170-88
pubmed: 10636297
Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9697-701
pubmed: 7568200